Oxygen is a hot commodity in space. It will be vital not only for potential human settlements to breathe, but also to enable the combustion processes needed to propel rockets to and from celestial bodies.
Nowadays, it’s often the case that 70 per cent of a rocket’s cargo consists of the oxygen needed to launch the spacecraft, which must be carried with it from Earth.
“One of the main challenges is the extraordinary cost of sending anything from Earth to the Moon,” Jonathan Geifman, the co-founder of Israeli company Project Helios, told Euronews.
If you’re gonna need a lot of supplies and fuel and bulk materials to go to Mars, you’re much better lifting them off the Moon than you are lifting them off the Earth.
Published: Mar 11, 2021 By Alex Keown
Saniona, a rare disease-focused company based in Sweden, received feedback from the U.S. Food and Drug Administration (FDA) on a path forward for its hypothalamic obesity (HO) drug Tesomet. Based on guidance from the regulatory agency, Saniona is planning a Phase IIb study in this indication in the first half of this year.
“There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” Rudolf Baumgartner, Chief Medical Officer and Head of Clinical Development at Saniona said in a statement. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase IIb clinical trial with Tesomet.”
Date Time
MD Anderson, Orionis launch Project Helios to advance new cancer medicines
The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.
Combining Orionis’ unique high-throughput drug discovery technologies with the Therapeutics Discovery division’s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing. The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future.
E-Mail
HOUSTON, BOSTON and GHENT, Belgium - The University of Texas MD Anderson Cancer Center s Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.
Combining Orionis unique high-throughput drug discovery technologies with the Therapeutics Discovery division s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing. The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future.
A long-running zoning dispute over housing on the Tap Root Dairy property finally came to an end while the land-use fight over an asphalt plant in East Flat Rock fizzled to an uncertain resolution. Downtown could be transformed by hotel and parking deck plans that neared the dirt-turning stage as the year drew to a close. Cloaked over every hour of every day from March 3 on was the coronavirus and its wide-ranging impacts. Covid-19 cases devastated long-term care facilities as the virus swept in. The pandemic claimed the Flat Rock Playhouse and Hendersonville Symphony Orchestra seasons, the North Carolina Apple Festival, prep football and more. Here are number 7, 6, 5 in the Lightning’s annual Top 10 news stories from an unforgettable year.